Oxygen therapy for COPD is a treatment used to increase the oxygen in your lungs and bloodstream. Research suggests that people with chronic obstructive pulmonary disease (COPD) who use oxygen may ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

—Early evidence suggests promise for a novel COPD treatment using autologous P63+ lung progenitor cell. This small study found the bronchoscopic transplantation of cultured P63+ cells to be safe and ...

COPD 5-year mortality was most likely in patients receiving long-term oxygen therapy, oral corticosteroids, and triple therapy. Increasing treatment intensity levels (TILs) in patients with chronic ...

Chronic obstructive pulmonary disease (COPD) makes it hard to breathe. Narrowed airways can make you cough, wheeze, and feel short of breath. It can affect how you exercise, work, and do other daily ...

Recent advances in non-pharmacological interventions have highlighted the role of singing and music therapy as promising adjuncts in the management of Chronic Obstructive Pulmonary Disease (COPD).

Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...